RVNC - Revance surges 45% as it sees revenue from RHA collection to be between $34M and $35M
- Revance Therapeutics ( NASDAQ: RVNC ) expects preliminary unaudited Q4 RHA collection revenue to be between $34M and $35M, a 45% rise Y/Y.
- ( RVNC ) has risen ~45%.
- Revance expects preliminary unaudited Daxxify revenue from PrevU, its early experience program, to be between $10.5M and $11.5M in the fourth quarter.
- Revance expects preliminary unaudited Q4 service revenue from Opul and the legacy HintMD fintech platform to be between $2.5M and $3.5M.
- It expects Non-GAAP operating expense guidance range of between $260M to $280M.
- Preliminary unaudited cash to be about $340M.
- "Looking ahead, our strategic priorities in the new year will center on delivering a successful commercial launch for DAXXIFY®, continuing the growth of our aesthetics portfolio, and unlocking our therapeutics opportunity by obtaining the FDA’s approval of DAXXIFY® for cervical dystonia," the company said.
For further details see:
Revance surges 45% as it sees revenue from RHA collection to be between $34M and $35M